Table 2.
Crude incidence rates of first serious infection: overall, lower respiratory tract infections, skin and soft tissue infections
| Treatment (n) | Total Person-Time, (Median Follow-Up Time) in Years | Infections | Rate per 1,000 Person-Years | 95% Confidence Interval in Person-Years |
|---|---|---|---|---|
| All serious infections | ||||
| Non-biologics (3,421) | 6,419.24 (1.51) | 91 | 14.18 | 11.54–17.41 |
| Methotrexate (2,118) | 3,422.40 (1.27) | 41 | 11.98 | 8.82–16.27 |
| Etanercept (1,352) | 3,278.20 (1.87) | 50 | 15.25 | 11.56–20.12 |
| Adalimumab (3,271) | 7,835.17 (1.97) | 108 | 13.78 | 11.41–16.64 |
| Ustekinumab (994) | 2,256.44 (2.00) | 34 | 15.07 | 10.77–21.09 |
| Lower respiratory tract infections | ||||
| Non-biologics | — | 27 | 4.21 | 2.88–6.13 |
| Methotrexate | — | 14 | 4.09 | 2.42–6.91 |
| Etanercept | — | 18 | 5.49 | 3.46–8.71 |
| Adalimumab | — | 31 | 3.96 | 2.78–5.63 |
| Ustekinumab | — | 12 | 5.32 | 3.02–9.36 |
| Skin and soft tissue infections | ||||
| Non-biologics | — | 22 | 3.43 | 2.26–5.20 |
| Methotrexate | — | 10 | 2.92 | 1.57–5.43 |
| Etanercept | — | 12 | 3.66 | 2.08–6.45 |
| Adalimumab | — | 19 | 2.42 | 1.55–3.80 |
| Ustekinumab | — | 8 | 3.55 | 1.77–7.09 |